Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, CRISPR Therapeutics AG's enterprise value is $3,594.39 Mil.
CRISPR Therapeutics AG's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-515.65 Mil. Therefore, CRISPR Therapeutics AG's EV-to-EBITDA for today is -6.97.
The historical rank and industry rank for CRISPR Therapeutics AG's EV-to-EBITDA or its related term are showing as below:
LTS:0VRQ'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -684.19 Med: -7.39 Max: 1665.17
Current: -6.97
During the past 12 years, the highest EV-to-EBITDA of CRISPR Therapeutics AG was 1665.17. The lowest was -684.19. And the median was -7.39.
LTS:0VRQ's EV-to-EBITDA is ranked worse than 100% of 409
companies
in the Biotechnology industry
Industry Median: 12.99
vs LTS:0VRQ: -6.97
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
CRISPR Therapeutics AG (LTS:0VRQ) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
CRISPR Therapeutics AG's PE Ratio (TTM) for today is calculated as:
CRISPR Therapeutics AG's share price for today is $53.75.
CRISPR Therapeutics AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.760.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0VRQ vs MANE, EWTX, CAI: EV-to-EBITDA Comparison
For the Biotechnology subindustry, CRISPR Therapeutics AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CRISPR Therapeutics AG EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where CRISPR Therapeutics AG's EV-to-EBITDA falls into.
CRISPR Therapeutics AG's current Enterprise Value is $3,594.39 Mil.
CRISPR Therapeutics AG's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-515.65 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRISPR Therapeutics AG (LTS:0VRQ) has a EV-to-EBITDA of -6.97 as of Aug. 08, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on CRISPR Therapeutics AG. According to the industry distribution chart, CRISPR Therapeutics AG ranks #999999 out of 409 companies in the Biotechnology industry.
Is CRISPR Therapeutics AG's EV-to-EBITDA too high?
CRISPR Therapeutics AG's current EV-to-EBITDA is -6.97. Based on the distribution chart, CRISPR Therapeutics AG ranks #999999 out of 409 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CRISPR Therapeutics AG has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CRISPR Therapeutics AG's EV-to-EBITDA compare to MANE and EWTX?
According to the Biotechnology industry distribution chart, CRISPR Therapeutics AG ranks #999999 out of 409 companies for EV-to-EBITDA. This places CRISPR Therapeutics AG in the lower half of its industry. The industry median EV-to-EBITDA is 12.99. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.99, based on 409 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on CRISPR Therapeutics AG. For the Biotechnology industry, the median EV-to-EBITDA is 12.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CRISPR Therapeutics AG's current EV-to-EBITDA is -6.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CRISPR Therapeutics AG stock overvalued right now?
Based on GuruFocus' analysis, CRISPR Therapeutics AG (LTS:0VRQ) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.30, compared to a current price of $53.75 — trading 1150% above its estimated fair value. The current EV-to-EBITDA is -6.97. CRISPR Therapeutics AG's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For CRISPR Therapeutics AG (LTS:0VRQ), the current EV-to-EBITDA is -6.97 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CRISPR Therapeutics AG (LTS:0VRQ) Overvalued in 2026?
Based on GuruFocus' analysis, CRISPR Therapeutics AG stock appears to be overvalued.
The current stock price of $53.75 is trading 1150% above its estimated GF Value™ of $4.30.
GuruFocus considers CRISPR Therapeutics AG to be Significantly Overvalued.
Key valuation signals for LTS:0VRQ:
EV-to-EBITDA: -6.97
GF Value™: $4.30 vs. price of $53.75 (1150% above fair value)
No single metric tells the full story. See the LTS:0VRQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
46GF Score
Get the complete analysis for LTS:0VRQ
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0VRQ has been successfully added to your 
